Target intelligence / Profile preview

Methionine adenosyltransferase 2 alpha (MAT2A)

Target: MAT2A
Molecular classification: Enzyme

Overview

Methionine adenosyltransferase 2 alpha (MAT2A) catalyzes the formation of S-adenosylmethionine (SAM) from methionine and ATP. SAM is the principal methyl donor in numerous biological methylation reactions. MAT2A is widely expressed and is a therapeutic target, particularly in cancers with MTAP deficiency. Inhibitors block its enzymatic activity, reducing intracellular SAM levels which can impair cancer cell proliferation.

Mechanism of action

Inhibition of MAT2A enzymatic activity, leading to reduced S-adenosylmethionine (SAM) levels

Biological functions

MethylationS-adenosylmethionine biosynthesisXenobiotic metabolism

Disease associations

Cancer

Biomarkers

MTAP loss (for patient selection)

Beyond the preview

Go deeper on Methionine adenosyltransferase 2 alpha (MAT2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methionine adenosyltransferase 2 alpha (MAT2A).

Explore the full profile